openPR Logo
Press release

Vernal Keratoconjunctivitis Market and Epidemiology 2032: Treatment Market, Therapies, Companies, FDA Approvals, Epidemiology and Forecast by DelveInsight | Santen SAS, Novartis, Laboratoires Thea, Allakos Inc., Santen SASl, Astellas Pharma

07-31-2023 06:58 PM CET | Health & Medicine

Press release from: DelveInsight Business Research

Vernal Keratoconjunctivitis Market and Epidemiology 2032:

DelveInsight's "Vernal Keratoconjunctivitis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Vernal Keratoconjunctivitis, historical and forecasted epidemiology as well as the Vernal Keratoconjunctivitis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Vernal Keratoconjunctivitis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Vernal Keratoconjunctivitis Market Forecast
https://www.delveinsight.com/sample-request/vernal-keratoconjunctivitis-market-insight?utm_source=benzinga&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Vernal Keratoconjunctivitis Market Report:
• The Vernal Keratoconjunctivitis market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• In the 7MM, there were 620,585 cases of vernal keratoconjunctivitis (VKC) overall in 2021
• According to estimations, there were 67,389 instances of VKC reported in the United States in 2021
• Italy has the highest prevalence of VKC among the EU4 and the UK, with 173,432 cases, followed by Germany and France. Spain, on the other hand, had the lowest prevalent population in 2021 with 16,072
• However, in 2021 in the United States, Mild covers 35.90% of the identified cases, Moderate includes 40.60%, and Severe includes 23.50%.
• Key Vernal Keratoconjunctivitis Companies: Santen SAS, Novartis, Laboratoires Thea, Allakos Inc., Santen SASl, Astellas Pharma Inc, and others
• Key Vernal Keratoconjunctivitis Therapies: NOVA22007 ''Ciclosporin", Cyclosporine A, N-acetyl-aspartyl-glutamate (NAAXIA Sine), AK002, Cyclosporine NOVA22007, FK506, and others
• The Vernal Keratoconjunctivitis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Vernal Keratoconjunctivitis pipeline products will significantly revolutionize the Vernal Keratoconjunctivitis market dynamics.

Vernal Keratoconjunctivitis Overview
Young, males are most frequently affected by vernal keratoconjunctivitis (VKC), a persistent allergic conjunctivitis. Even while the majority of allergic conjunctivitis types do not impair vision, VKC is uncommon in that it can cause vision loss if the cornea is damaged.

Get a Free sample for the Vernal Keratoconjunctivitis Market Report
https://www.delveinsight.com/report-store/vernal-keratoconjunctivitis-market-insight?utm_source=benzinga&utm_medium=pressrelease&utm_campaign=gpr

Vernal Keratoconjunctivitis Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Vernal Keratoconjunctivitis Epidemiology Segmentation:
The Vernal Keratoconjunctivitis market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of Vernal Keratoconjunctivitis
• Prevalent Cases of Vernal Keratoconjunctivitis by severity
• Gender-specific Prevalence of Vernal Keratoconjunctivitis
• Diagnosed Cases of Episodic and Chronic Vernal Keratoconjunctivitis

Download the report to understand which factors are driving Vernal Keratoconjunctivitis epidemiology trends @ Vernal Keratoconjunctivitis Epidemiology Forecast
https://www.delveinsight.com/sample-request/vernal-keratoconjunctivitis-market-insight?utm_source=benzinga&utm_medium=pressrelease&utm_campaign=gpr

Vernal Keratoconjunctivitis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Vernal Keratoconjunctivitis market or expected to get launched during the study period. The analysis covers Vernal Keratoconjunctivitis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Vernal Keratoconjunctivitis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Vernal Keratoconjunctivitis Therapies and Key Companies
• NOVA22007 ''Ciclosporin": Santen SAS
• Cyclosporine A: Novartis
• N-acetyl-aspartyl-glutamate (NAAXIA Sine): Laboratoires Thea
• AK002: Allakos Inc.
• Cyclosporine NOVA22007: Santen SAS
• FK506: Astellas Pharma Inc

Discover more about therapies set to grab major Vernal Keratoconjunctivitis market share @ Vernal Keratoconjunctivitis Treatment Market
https://www.delveinsight.com/sample-request/vernal-keratoconjunctivitis-market-insight?utm_source=benzinga&utm_medium=pressrelease&utm_campaign=gpr

Scope of the Vernal Keratoconjunctivitis Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Vernal Keratoconjunctivitis Companies: Santen SAS, Novartis, Laboratoires Thea, Allakos Inc., Santen SASl, Astellas Pharma Inc, and others
• Key Vernal Keratoconjunctivitis Therapies: NOVA22007 ''Ciclosporin", Cyclosporine A, N-acetyl-aspartyl-glutamate (NAAXIA Sine), AK002, Cyclosporine NOVA22007, FK506, and others
• Vernal Keratoconjunctivitis Therapeutic Assessment: Vernal Keratoconjunctivitis current marketed and Vernal Keratoconjunctivitis emerging therapies
• Vernal Keratoconjunctivitis Market Dynamics: Vernal Keratoconjunctivitis market drivers and Vernal Keratoconjunctivitis market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Vernal Keratoconjunctivitis Unmet Needs, KOL's views, Analyst's views, Vernal Keratoconjunctivitis Market Access and Reimbursement

To know more about Vernal Keratoconjunctivitis companies working in the treatment market, visit @ Vernal Keratoconjunctivitis Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/vernal-keratoconjunctivitis-market-insight?utm_source=benzinga&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Vernal Keratoconjunctivitis Market Report Introduction
2. Executive Summary for Vernal Keratoconjunctivitis
3. SWOT analysis of Vernal Keratoconjunctivitis
4. Vernal Keratoconjunctivitis Patient Share (%) Overview at a Glance
5. Vernal Keratoconjunctivitis Market Overview at a Glance
6. Vernal Keratoconjunctivitis Disease Background and Overview
7. Vernal Keratoconjunctivitis Epidemiology and Patient Population
8. Country-Specific Patient Population of Vernal Keratoconjunctivitis
9. Vernal Keratoconjunctivitis Current Treatment and Medical Practices
10. Vernal Keratoconjunctivitis Unmet Needs
11. Vernal Keratoconjunctivitis Emerging Therapies
12. Vernal Keratoconjunctivitis Market Outlook
13. Country-Wise Vernal Keratoconjunctivitis Market Analysis (2019-2032)
14. Vernal Keratoconjunctivitis Market Access and Reimbursement of Therapies
15. Vernal Keratoconjunctivitis Market Drivers
16. Vernal Keratoconjunctivitis Market Barriers
17. Vernal Keratoconjunctivitis Appendix
18. Vernal Keratoconjunctivitis Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Related Reports:
Vernal Keratoconjunctivitis Pipeline
https://www.delveinsight.com/report-store/vernal-keratoconjunctivitis-pipeline-insight?utm_source=benzinga&utm_medium=pressrelease&utm_campaign=gpr
"Vernal Keratoconjunctivitis Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Vernal Keratoconjunctivitis market. A detailed picture of the Vernal Keratoconjunctivitis pipeline landscape is provided, which includes the disease overview and Vernal Keratoconjunctivitis treatment guidelines.
Vernal Keratoconjunctivitis Epidemiology
https://www.delveinsight.com/report-store/vernal-keratoconjunctivitis-epidemiology-forecast?utm_source=benzinga&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Vernal Keratoconjunctivitis Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Vernal Keratoconjunctivitis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports by DelveInsight

Monkeypox Market https://www.delveinsight.com/report-store/monkeypox-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Monkeypox Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Monkeypox, historical and forecasted epidemiology as well as the Monkeypox market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Pars Planitis Market
https://www.delveinsight.com/report-store/pars-plantis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Pars Plantis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Pars Plantis, historical and forecasted epidemiology as well as the Pars Plantis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Patient Monitoring Devices Market
https://www.delveinsight.com/report-store/patient-monitoring-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Patient Monitoring Devices Market By Type Of Devices (Neuromonitoring Devices, Cardiac Monitoring Devices, Respiratory Monitoring Devices, Hemodynamic Monitoring Devices, Blood Glucose Monitoring Systems, And Others), By Application (Cardiology, Neurology, Respiratory, And Others), By End-User (Hospitals & Clinics, Ambulatory Surgical Centers, Home Care Settings, And Others), by geography, is anticipated to grow at a significant CAGR till 2028 owing to the growing prevalence of various chronic disorders and integration of advanced technology in the products

Typhoid Market https://www.delveinsight.com/report-store/typhoid-fever-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Typhoid Fever Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Typhoid Fever, historical and forecasted epidemiology as well as the Typhoid Fever market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Zika Virus Market https://www.delveinsight.com/report-store/zika-virus-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Zika Virus Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Zika Virus, historical and forecasted epidemiology as well as the Zika Virus market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Opioid Use Disorder Market https://www.delveinsight.com/report-store/opioid-use-disorder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Opioid Use Disorder (OUD) - Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the Opioid Use Disorder (OUD), historical and forecasted epidemiology as well as the Opioid Use Disorder (OUD) market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Recent Blog's By DelveInsight:
• Insights Into The Cutaneous T-cell Lymphoma Treatment Market
https://www.delveinsight.com/blog/cutaneous-t-cell-lymphoma-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Roche's HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape
https://www.delveinsight.com/blog/hemlibra-for-hemophilia-a-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Emerging Role of Digital Health in the Field of Oncology
https://www.delveinsight.com/blog/digital-health-to-improve-cancer-management?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape
https://www.delveinsight.com/blog/evolving-als-treatment-landscape?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How are Technological Trends and Innovations Reshaping the Dementia Care
https://www.delveinsight.com/blog/technological-innovations-in-dementia-care?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market
https://www.delveinsight.com/blog/clinical-diagnostics-market-outlook?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients
https://www.delveinsight.com/blog/non-opioid-analgesics-for-chronic-pain-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market
https://www.delveinsight.com/blog/alpha-1-antitrypsin-deficiency-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Evaluating the Key Trends and Technologies Shaping the Future of Dentistry https://www.delveinsight.com/blog/emerging-trends-in-dental-care-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Vernal Keratoconjunctivitis Market and Epidemiology 2032: Treatment Market, Therapies, Companies, FDA Approvals, Epidemiology and Forecast by DelveInsight | Santen SAS, Novartis, Laboratoires Thea, Allakos Inc., Santen SASl, Astellas Pharma here

News-ID: 3150712 • Views:

More Releases from DelveInsight Business Research

Primary Biliary Cholangitis Market Expected to Experience Major Growth by 2034, According to DelveInsight
Primary Biliary Cholangitis Market Expected to Experience Major Growth by 2034, …
DelveInsight's "Primary Biliary Cholangitis Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Primary Biliary Cholangitis, historical and forecasted epidemiology as well as the Primary Biliary Cholangitis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. To Know in detail about the Primary Biliary Cholangitis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Primary Biliary Cholangitis
Advanced Renal Cell Carcinoma Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight
Advanced Renal Cell Carcinoma Pipeline 2025: Therapies, MOA Insights, and Key Cl …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Advanced Renal Cell Carcinoma pipeline constitutes 50+ key companies continuously working towards developing 60+ Advanced Renal Cell Carcinoma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. "Advanced Renal Cell Carcinoma Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across
Alport Syndrome Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight
Alport Syndrome Market Forecasted to Surge in Coming Years, 2024-2034 Analysis b …
DelveInsight's "Alport Syndrome Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Alport Syndrome, historical and forecasted epidemiology as well as the Alport Syndrome market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. To Know in detail about the Alport Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Alport Syndrome Market Forecast https://www.delveinsight.com/sample-request/alport-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Some of the
Angioedema Pipeline 2025: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight
Angioedema Pipeline 2025: FDA Approvals and Clinical Trials Landscape with MOA a …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Angioedema pipeline constitutes 20+ key companies continuously working towards developing 20+ Angioedema treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. The Angioedema Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed

All 5 Releases


More Releases for Vernal

Vernal Keratoconjunctivitis (VKC) Market to Reach USD 688.4 Million by 2034
Pune, India - December 2025 - The global Vernal Keratoconjunctivitis (VKC) Market, valued at USD 402.2 million in 2024, is projected to reach USD 688.4 million by 2034, growing at a 5.5% CAGR (2025-2034), according to Exactitude Consultancy. Increasing prevalence of allergic eye disorders, growing pediatric patient population, and expansion of advanced anti-inflammatory and immunomodulatory therapies are driving strong market growth. Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/72220 Market
Vernal Keratoconjunctivitis Market: Biologics and Digital Tools Drive Growth to …
Subheadline: Rising global prevalence in warm climates, growing use of biologic eye drops, and digital ophthalmology advancements are fueling the vernal keratoconjunctivitis (VKC) market worldwide. Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/72220 Introduction The Vernal Keratoconjunctivitis (VKC) Market is expanding steadily as patient awareness, targeted biologic drugs, and improved diagnostic tools transform allergic eye-disease management. Valued at USD 430 million in 2024, the market is projected to reach around USD 780 million
Vernal Keratoconjunctivitis Drugs Market Statistical Forecast, Trade Analysis 20 …
DataM Intelligence has published a new research report on "Vernal Keratoconjunctivitis Drugs Market Size 2024". The report explores comprehensive and insightful Information about various key factors like Regional Growth, Segmentation, CAGR, Business Revenue Status of Top Key Players and Drivers. The purpose of this report is to provide a telescopic view of the current market size by value and volume, opportunities, and development status. Get a Free Sample Research PDF
Change Your Perception of Space with Vernal Washable Geometric Rugs
Green Decore, a leading innovator in home decor, is thrilled to introduce its latest innovation: the Geometric Rugs from the Vernal Washable Rug Collection. Designed to transform your living spaces with style, ease and affordability, these rugs redefine the way you think about floor coverings. https://www.greendecore.co.uk/collections/washable-indoor-rugs Green Decore is known for its commitment to creating stylish and versatile home decor solutions. The Vernal Rug Collection continues this tradition by offering a
Enliven The Majestic Beauty of Persian Rugs by Vernal Rug Collection
Green Decore, a leading name in innovative floor decor solutions, proudly introduces the Vernal Rug Collection, an exquisite array of Persian rugs that combine timeless elegance with modern convenience. Unveiling the true essence of Persian artistry, the Vernal Rug Collection offers a range of machine washable rugs, embodying the perfect blend of tradition and technology. https://www.greendecore.co.uk/collections/persian-rugs Synonymous with opulence and sophistication, Persian rugs have always been a symbol of luxury and
Green Decore Showcases Their Exciting Lineup of Vernal Machine Washable Indoor R …
Green Decore, a leading brand in the home decor industry, has recently added new designs to their Vernal Collection of Machine Washable Indoor Rugs. The brand is renowned for its high-quality, stylish and durable home decor items and their latest collection of Vernal Washable Rugs is no exception. https://www.greendecore.co.uk/collections/washable-indoor-rugs The new designs of washable indoor rugs are available in a variety of colours and sizes, allowing homeowners to choose the perfect